The effectiveness and value of tabelecleucel for the treatment of Epstein-Barr virus-positive posttransplant lymphoproliferative disease.
作者信息
McKenna Avery, Lin Grace A, Lee Woojung, Raymond Finn, Richardson Marina, Agboola Foluso
机构信息
Institute for Clinical and Economic Review, Boston, MA.
出版信息
J Manag Care Spec Pharm. 2025 Apr;31(4):429-434. doi: 10.18553/jmcp.2025.31.4.429.
Abstract
摘要
相似文献
1
The effectiveness and value of tabelecleucel for the treatment of Epstein-Barr virus-positive posttransplant lymphoproliferative disease.他克莫司治疗爱泼斯坦-巴尔病毒阳性移植后淋巴细胞增生性疾病的有效性和价值。
J Manag Care Spec Pharm. 2025 Apr;31(4):429-434. doi: 10.18553/jmcp.2025.31.4.429.
2
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.塔布雷塞莱珠单抗治疗利妥昔单抗或利妥昔单抗联合化疗失败后发生 EBV 阳性移植后淋巴增殖性疾病的异基因造血干细胞或实体器官移植受者（ALLELE）：一项 3 期、多中心、开放标签试验。
Lancet Oncol. 2024 Mar;25(3):376-387. doi: 10.1016/S1470-2045(23)00649-6. Epub 2024 Jan 31.
3
Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.造血细胞移植或实体器官移植后 EBV 阳性移植后淋巴组织增生性疾病患者中 tabelecleucel 与现有治疗的比较分析。
J Med Econ. 2024 Jan-Dec;27(1):789-795. doi: 10.1080/13696998.2024.2354150. Epub 2024 Jun 3.
4
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV PTLD).多准则决策分析（MCDA）在决策中进行反思性讨论的价值：以确定 tabelecleucel 治疗 EBV 阳性移植后淋巴组织增生性疾病（EBV PTLD）的价值贡献为例。
Orphanet J Rare Dis. 2024 Aug 23;19(1):308. doi: 10.1186/s13023-024-03324-5.
5
Epstein-Barr virus DNAemia in Iranian liver transplant recipients and assessment of its variation in posttransplant lymphproliferative disorder patients by quantitative polymerase chain reaction assay.伊朗肝移植受者中的爱泼斯坦-巴尔病毒血症以及通过定量聚合酶链反应测定评估移植后淋巴增殖性疾病患者中该病毒的变异情况。
Exp Clin Transplant. 2015 Apr;13 Suppl 1:306-11. doi: 10.6002/ect.mesot2014.p148.
6
Role of Cytomegalovirus in the Development of Posttransplant Lymphoproliferative Disorders With or Without Epstein-Barr Virus Infection.巨细胞病毒在移植后淋巴组织增生性疾病（伴或不伴 Epstein-Barr 病毒感染）发展中的作用。
Exp Clin Transplant. 2022 Aug;20(8):757-761. doi: 10.6002/ect.2021.0433. Epub 2022 Jan 14.
7
Hepatitis C virus infection can affect lymphoproliferative disorders only as a cofactor for Epstein-Barr virus in liver transplant recipients: PTLD.Int survey.丙型肝炎病毒感染仅作为肝移植受者中 Epstein-Barr 病毒导致淋巴增殖性疾病（PTLD）的一个辅助因素发挥作用：国际调查。
Exp Clin Transplant. 2012 Apr;10(2):141-7. doi: 10.6002/ect.2011.0114.
8
9
Tabelecleucel: First Approval.塔贝莱克塞尔：首次获批。
Mol Diagn Ther. 2023 May;27(3):425-431. doi: 10.1007/s40291-023-00648-z. Epub 2023 Apr 5.
10
A pediatric case series of catastrophic gastrointestinal complications of posttransplant lymphoproliferative disease with increasing incidence, high association with coronavirus disease 2019, higher mortality, and a plea for early endoscopy to prevent late fatal outcome.儿童移植后淋巴组织增生性疾病灾难性胃肠道并发症的病例系列，发病率增加，与 2019 年冠状病毒病的关联性高，死亡率高，并呼吁尽早进行内镜检查以预防晚期致命后果。
J Med Case Rep. 2023 Sep 19;17(1):396. doi: 10.1186/s13256-023-04123-5.
本文引用的文献
1
Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.造血细胞移植或实体器官移植后 EBV 阳性移植后淋巴组织增生性疾病患者中 tabelecleucel 与现有治疗的比较分析。
J Med Econ. 2024 Jan-Dec;27(1):789-795. doi: 10.1080/13696998.2024.2354150. Epub 2024 Jun 3.
2
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.在多中心扩展准入方案中，异体造血干细胞移植或实体器官移植后 EBV+PTLD 应用 Tabelecleucel。
Blood Adv. 2024 Jun 25;8(12):3001-3012. doi: 10.1182/bloodadvances.2023011626.
3
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.塔布雷塞莱珠单抗治疗利妥昔单抗或利妥昔单抗联合化疗失败后发生 EBV 阳性移植后淋巴增殖性疾病的异基因造血干细胞或实体器官移植受者（ALLELE）：一项 3 期、多中心、开放标签试验。
Lancet Oncol. 2024 Mar;25(3):376-387. doi: 10.1016/S1470-2045(23)00649-6. Epub 2024 Jan 31.
4
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy.利妥昔单抗治疗失败后异基因造血干细胞移植后 EBV 阳性 PTLD 患者的结局。
Bone Marrow Transplant. 2024 Jan;59(1):52-58. doi: 10.1038/s41409-023-02127-9. Epub 2023 Oct 21.
5
Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status.医疗保险资格患者肾移植后移植后淋巴组织增生性疾病的成本负担按生存状况划分。
J Med Econ. 2021 Jan-Dec;24(1):620-627. doi: 10.1080/13696998.2021.1915793.
6
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.现成的EBV特异性T细胞免疫疗法用于移植后利妥昔单抗难治性EBV相关淋巴瘤。
J Clin Invest. 2020 Feb 3;130(2):733-747. doi: 10.1172/JCI121127.
7
Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.移植后淋巴组织增生性疾病、爱泼斯坦-巴尔病毒感染和实体器官移植中的疾病：美国移植感染病学会实践社区指南。
Clin Transplant. 2019 Sep;33(9):e13652. doi: 10.1111/ctr.13652. Epub 2019 Jul 23.
8
Post-Transplantation Lymphoproliferative Disorders in Adults.成人移植后淋巴增殖性疾病
N Engl J Med. 2018 Feb 8;378(6):549-562. doi: 10.1056/NEJMra1702693.
9
Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.实体器官移植后爱泼斯坦-巴尔病毒阳性移植后淋巴增殖性疾病：发病机制、临床表现、诊断及管理
Transplant Direct. 2015 Dec 15;2(1):e48. doi: 10.1097/TXD.0000000000000557. eCollection 2016 Jan.
Zotero 插件